Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine/Cedazuridine + Magrolimab in MDS
NCT05835011Phase 2Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of magrolimab in myelodysplastic syndrome (MDS), sponsored by Astex Pharmaceuticals. Primary endpoints: Adverse Events, Dose-Limiting Toxicities and 1 more. Started Jun 2023; status: terminated.
02
Drugs
magrolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05835011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835011.